07:00 , Mar 30, 2015 |  BioCentury  |  Finance

Poland backing innovators

The Polish government is backing the country's first life sciences VC to help build innovative life science companies in a country known for its services-oriented healthcare sector. While the capital and infrastructure are available, one...
07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Xellia Pharmaceuticals A/S, Novo A/S deal

*** Xellia Pharmaceuticals A/S , Oslo, Norway   Novo A/S , Hellerup, Denmark   Business: Infectious   Novo will acquire infectious disease company Xellia from private equity firm 3i Group and other shareholders for about...
00:01 , May 22, 2013 |  BC Extra  |  Company News

Novo A/S acquires Xellia

Novo A/S (Hellerup, Denmark) will acquire infectious disease company Xellia Pharmaceuticals A/S (Oslo, Norway) from private equity firm 3i Group for about $700 million. In 2008, 3i acquired Xellia, which develops and manufactures active pharmaceutical...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Biomet 3i LLC, Innocoll sales and marketing update

Innocoll granted Biomet 3i exclusive, worldwide rights to commercialize Innocoll's CollaCare Dental products outside China and countries in the Association of Southeast Asian Nations (ASEAN), where Innocoll is partnered with Pioneer Pharma Co. Ltd. (Haikou,...
07:00 , Oct 10, 2011 |  BioCentury  |  Finance

Buyside tracks

Buyside tracks Stefan Mueller will depart from...
07:00 , May 9, 2011 |  BioCentury  |  Finance

Sweet on diagnostics

Sweet on diagnostics...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Company News

OctoPlus management update

OctoPlus N.V. (Euronext:OCTO), Leiden, the Netherlands   Business: Drug delivery   Departing: CEO Simon Sturge, effective Jan. 1, 2011; the company's board nominated Jan Egberts, formerly senior advisor in healthcare investments for 3i Group and...
00:26 , Nov 5, 2010 |  BC Extra  |  Company News

OctoPlus CEO Sturge leaving

Drug delivery company OctoPlus N.V. (Euronext:OCTO) said CEO Simon Sturge will depart on Jan. 1, 2011, to lead a division of an undisclosed pharmaceutical company. The company's board nominated Jan Egberts for appointment as CEO...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Private equity tracks

Private equity tracks Bernie Schuler joined...